RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Commercialization phase - Jan 2023 to December 2025Endocyte asked the same questions.. turns out 2.1b answered that question for their radionucleotide and made shareholders happy
not some existential question about how with a few million engaging in a deep conversation about learning curves and capabilities.
the answer is.. TLT has gone as far as it can go...... the PP in 2019 was for NMIBC and that's it..
luckily the Phase 2 is Pivotal.... NO phase 3 required.
Endocyte was just exiting phase 2 enterring phase 3 basically..
Endocyte The takeover values Endocyte at $24 a share. At the company’s lowest ebb in the weeks before the ABX deal, Endocyte’s stock traded for as little as $1.17 a share. The ABX deal turned Endocyte from a flailing biotech into a rising company with a leading clinical-phase radioligand therapeutic, triggering a jump in its stock price that continued as it posted more phase 2 data and moved into phase 3.
Endocyte looked set to spend the next year or so working toward phase 3 data before Novartis stepped in.
TBH this is exhausting.. we know where we are....... and it's damn near that time to make bank.. this year in 2022.
jmm1228 wrote: How will TLT carry on the establishment of a full scale market ing/manufacturing/distribution operation
with the assets presently at hand?
What is the best way to establish such expediently given the current lack of these vital capabilities and the long dwell time to establish. The learning curve is steep!
What entities believe they are best positioned to handle the matter?
Stay tuned, something will happen, the status quo won't carry this off.